The patent application WO2018117152A1, published by Google Patents, describes delgocitinib, a Janus kinase (JAK) inhibitor. This application, filed by AnaptysBio, Inc., relates to pharmaceutical compositions containing delgocitinib and methods of treating inflammatory diseases. Delgocitinib is investigated for its potential in conditions like rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.
What is delgocitinib and how does it work?
Delgocitinib is an orally administered, selective inhibitor of Janus kinases (JAKs), specifically targeting JAK1 and JAK2 [1]. JAKs are intracellular enzymes that play a crucial role in signaling pathways involved in inflammation and immune responses. By inhibiting these enzymes, delgocitinib aims to reduce the inflammatory processes underlying various autoimmune and inflammatory diseases [1].
What conditions is delgocitinib being developed for?
Delgocitinib is being explored for the treatment of several inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis [1]. The patent application details its potential therapeutic applications in these disease areas.
When does the patent for delgocitinib expire?
Patent expiry dates are complex and depend on various factors, including the specific patent filings, geographical regions, and any granted extensions or challenges. Information regarding the specific patent expiry for delgocitinib can be found through dedicated patent databases. DrugPatentWatch.com is a resource that tracks drug patents and exclusivity timelines.
Are there other JAK inhibitors available or in development?
Yes, the field of JAK inhibitors is active, with several other drugs approved and under development. These include tofacitinib, baricitinib, and upadacitinib, among others. Each JAK inhibitor may have varying selectivity profiles for different JAK isoforms, potentially leading to different efficacy and safety profiles.
What are the potential risks and side effects of JAK inhibitors?
JAK inhibitors, as a class, carry potential risks that have been identified through clinical trials and post-market surveillance. These can include an increased risk of serious infections, blood clots, cardiovascular events, and certain types of cancer [2]. Specific risks associated with delgocitinib would be detailed in its clinical trial data and regulatory reviews.
Where can I find more information on delgocitinib patents?
For detailed information on patents related to delgocitinib, including filing dates, inventors, and jurisdictions, patent search engines like Google Patents can be utilized. Resources such as DrugPatentWatch.com also provide comprehensive data on drug patents and market exclusivity.
What is the regulatory status of delgocitinib?
The regulatory status of delgocitinib depends on ongoing clinical trials and submissions to health authorities like the FDA and EMA. Information on its approval status for specific indications would be available through regulatory agency websites and pharmaceutical company announcements.
*
**Sources:
[1] WO2018117152A1 - Delgocitinib patent application (via Google Patents)
[2] U.S. Food & Drug Administration (FDA) - Safety Communications (General information on JAK inhibitors)